TR201901309T4 - Semiflorlanmış alkanları içeren o/w emülsiyonları. - Google Patents

Semiflorlanmış alkanları içeren o/w emülsiyonları. Download PDF

Info

Publication number
TR201901309T4
TR201901309T4 TR2019/01309T TR201901309T TR201901309T4 TR 201901309 T4 TR201901309 T4 TR 201901309T4 TR 2019/01309 T TR2019/01309 T TR 2019/01309T TR 201901309 T TR201901309 T TR 201901309T TR 201901309 T4 TR201901309 T4 TR 201901309T4
Authority
TR
Turkey
Prior art keywords
emulsions containing
semifluorinated alkanes
compositions
containing semifluorinated
alkane
Prior art date
Application number
TR2019/01309T
Other languages
English (en)
Inventor
Theisinger Bastian
Theisinger Sonja
Günther Bernhard
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of TR201901309T4 publication Critical patent/TR201901309T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, bir semiflorlanmış alkan içeren fiziksel olarak kararlı emülsiyonlar formunda sıvı bileşimler sağlar. Semi florlanmış alkan, aktif bir farmasötik madde de içerebilen dağılmış fazda bulunur. Tercih edilen aktif bileşenlerden biri propofoldur. Bileşimler isteğe bağlı olarak ısı ile sterilize edilebilir ve farmasötik veya kozmetik ürün uygulamaları için kullanılabilir ve topikal, damar içi veya başka yollarla uygulanabilir.
TR2019/01309T 2011-01-04 2012-01-03 Semiflorlanmış alkanları içeren o/w emülsiyonları. TR201901309T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11150064 2011-01-04

Publications (1)

Publication Number Publication Date
TR201901309T4 true TR201901309T4 (tr) 2019-02-21

Family

ID=43978091

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2018/08752T TR201808752T4 (tr) 2011-01-04 2012-01-03 Semiflorlanmış alkanları içeren o/w emülsiyonları.
TR2019/01309T TR201901309T4 (tr) 2011-01-04 2012-01-03 Semiflorlanmış alkanları içeren o/w emülsiyonları.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2018/08752T TR201808752T4 (tr) 2011-01-04 2012-01-03 Semiflorlanmış alkanları içeren o/w emülsiyonları.

Country Status (15)

Country Link
US (5) US20140004197A1 (tr)
EP (2) EP3202421B1 (tr)
JP (1) JP6073244B2 (tr)
KR (1) KR101910213B1 (tr)
CN (1) CN103313729B (tr)
AU (1) AU2012204932B2 (tr)
BR (1) BR112013016661B1 (tr)
CA (1) CA2819988C (tr)
DK (2) DK3202421T3 (tr)
ES (2) ES2675242T3 (tr)
MX (1) MX353154B (tr)
PL (2) PL2661280T3 (tr)
PT (2) PT3202421T (tr)
TR (2) TR201808752T4 (tr)
WO (1) WO2012093113A1 (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103596554A (zh) 2011-05-25 2014-02-19 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
ES2965828T3 (es) 2012-09-12 2024-04-17 Novaliq Gmbh Composiciones de alcano semifluorado
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
GB2511028A (en) * 2012-12-18 2014-08-27 Univ Manchester Metropolitan Nano emulsions, methods of forming the same and uses thereof
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
US20160354340A1 (en) * 2014-03-03 2016-12-08 Encore Vision Inc. Lipoic acid choline ester compositions and methods of use
EP3355990B1 (en) 2015-09-30 2019-06-12 Novaliq GmbH Semifluorinated compounds and their compositions
CN110693825B (zh) 2015-09-30 2022-03-08 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
PL3515420T3 (pl) 2016-09-22 2024-04-08 Novaliq Gmbh Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
EP3856128B1 (en) 2018-09-27 2023-06-07 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
JP2022502421A (ja) 2018-10-12 2022-01-11 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache
FR3112475B1 (fr) 2020-07-20 2023-11-10 Naos Inst Of Life Science formulation écobiologique, compatible avec la vie cellulaire, utilisable dans les domaines cosmétiques, dermopharmaceutiques ou vétérinaires
JP2024508686A (ja) * 2021-02-05 2024-02-28 エパレックス コーポレーション フォスプロポフォールの方法及び組成物
DE102021005495A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
DE102021005494A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
EP1105096B1 (en) * 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
WO2000054588A1 (en) 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
JP2007511616A (ja) * 2003-11-19 2007-05-10 バーンズ−ジューイッシュ ホスピタル 増強された薬物送達
ATE420625T1 (de) 2005-08-05 2009-01-15 Bharat Serums & Vaccines Ltd Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Also Published As

Publication number Publication date
TR201808752T4 (tr) 2018-07-23
PL3202421T3 (pl) 2018-10-31
CN103313729A (zh) 2013-09-18
EP2661280A1 (en) 2013-11-13
MX353154B (es) 2017-12-20
PT3202421T (pt) 2018-07-03
JP2014501270A (ja) 2014-01-20
EP3202421B1 (en) 2018-03-28
PT2661280T (pt) 2019-02-25
MX2013007807A (es) 2013-12-16
CA2819988C (en) 2019-11-12
CN103313729B (zh) 2016-11-09
CA2819988A1 (en) 2012-07-12
BR112013016661B1 (pt) 2021-08-03
US20200360285A1 (en) 2020-11-19
EP3202421A1 (en) 2017-08-09
US20190224123A1 (en) 2019-07-25
AU2012204932B2 (en) 2017-02-23
ES2675242T3 (es) 2018-07-09
DK2661280T3 (en) 2019-03-04
US20140004197A1 (en) 2014-01-02
KR20140003477A (ko) 2014-01-09
AU2012204932A1 (en) 2013-07-04
BR112013016661A2 (pt) 2016-10-04
US20170216204A1 (en) 2017-08-03
JP6073244B2 (ja) 2017-02-01
US20230139672A1 (en) 2023-05-04
ES2711760T3 (es) 2019-05-07
PL2661280T3 (pl) 2019-05-31
WO2012093113A1 (en) 2012-07-12
EP2661280B1 (en) 2018-11-21
KR101910213B1 (ko) 2018-12-19
DK3202421T3 (en) 2018-07-16

Similar Documents

Publication Publication Date Title
TR201901309T4 (tr) Semiflorlanmış alkanları içeren o/w emülsiyonları.
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CO7111300A2 (es) Formulación de anticuerpos
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CL2016000188A1 (es) Composiciones de arní de serpinc1 y métodos de uso de las mismas
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
BR112015004185A2 (pt) composições antiperspirantes em aerossol, produtos e métodos
EA201990820A1 (ru) Способы лечения митохондриальных и метаболических нарушений
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112015032341A2 (pt) conservação de composições para cuidados pessoais
NI201500096A (es) Compuesto químicos
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
BR112015022923A2 (pt) derivados de imidazopiridina microbicidamente ativos
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
EA202191803A2 (ru) Смешанные составы
BR112019008673B8 (pt) Composição antitranspirante e método para a redução da transpiração
TH136512B (th) สารละลายเรตินอยด์ชนิดใช้เฉพาะที่
TH165384B (th) สูตรผสมสารรวมทางเภสัชกรรมที่ประกอบรวมด้วยแอมโลดิปีน, ลอซาร์แทน และโรซูวาสแตติน